Войти в систему
Войти с помощью соц. сетей:
Эта книга – результат командной работы. Мне повезло работать с двумя выдающимися редакторами, Меган Ньюман и Ниной Шилд, вдумчивым и поддерживающим агентом Скоттом Ваксманом (действительно ли это было десятилетие?), а также с талантливой командой Penguin Random House: Кейси Мэлони, Линдси Гордон, Фарин Шлюссел, Ханной Штайгмейер и Аллиссой Касофф. Я также хочу поблагодарить команды в Нью-Смирна-Бич, Ирвингтоне, Махопаке, Арлингтоне, Вейле Корнелле и Аллергане за их терпение и поддержку и хочу поставить пятерку редактору, который знает об Eagles больше, чем кто-либо. Не принимайте это близко к сердцу!
Мне повезло, что у меня есть группа близких друзей – Рэйчел, Чарли, Джон и Бен, и я в долгу перед Кевином Даутеном за его столь необходимый юмор и Эден Лаас за тщательный фактчекинг. В конечном счете это история о пациентах, и я очень благодарен мужчинам и женщинам, которые воспользовались нашим клиническим исследованием. Спасибо за вашу щедрость и мужество.
Хизер, я не уверен, что когда-нибудь полностью выскажу, что ты для меня значишь, но каждый день с тобой прекрасен. Спасибо, что показала мне, что значит быть жестким и добрым. Не могу дождаться, чтобы увидеть, что будет дальше.
Мэтт Маккарти – автор двух бестселлеров: «The Real Doctor Will See You Shortly» и «Odd Man Out». Доцент медицины в медцентре Вейла Корнелла и штатный врач нью-йоркской пресвитерианской больницы, где работает в Комитете по этике. Его работы появились в Sports Illustrated, Slate, Медицинском журнале Новой Англии и Deadspin. Он рецензирует научную литературу для USA Today и является главным редактором Current Fungal Infection Reports.
1. Coates A.R., Hu Y. Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol. 2007; 152(8):1147-54.
2. Fleming A. Discussion on Vaccine Therapy: its Treatment, Value, and Limitations. Proc R Soc Med. 1910; 3 (Gen Rep):137-9.
3. Adami J.G., Bowman F.B., Adams F., Fleming A.G., Farquharson C.D., Imrie C., et al. Combined Inquiry into the Presence of Diphtheria and Diphtheroid Bacilli in Open Wounds. Can Med Assoc J. 1918;8(9):769-85.
4. Munroe A.R., Fleming A.G., Janes R.M. Wound flora in relation to secondary suture. Br Med J. 1918;1(2980):173.
5. Fleming A. A British Medical Association Lecture on vaccine therapy in regard to general practice. Br Med J. 1921;1(3138):255-9.
6. Fleming A. The Bactericidal Power of Human Blood and some Methods of Altering It. Proc R Soc Med. 1928;21(5):859-68.
7. Fleming A. Lysozyme: President’s Address. Proc R Soc Med. 1932;26(2):71–84.
8. Fleming A. The assay of penicillin in the days before it was concentrated. Health Organ Bull. 1945;12(2):250-2.
9. Fleming A. Antiseptics, old and new. Proc Staff Meet Mayo Clin. 1946;21:67–75.
10. Fleming A. The development and use of penicillin. Chic Med Sch Q. 1946;7(2):20-8.
11. Fleming A.,Smith C. Estimation of penicillin in serum; use of glucose, phenol red, and serum water. Lancet. 1947;1(6448):401.
12. Fleming A.,Walters W. Penicillin in surgery. Lancet. 1947;2(6474):479.
13. Fleming A. Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226–236, 1929. Rev Infect Dis. 1980;2(1):129-39.
14. Morphy A.G. Thoughts by a physician on the battle of the marne. Can Med Assoc J. 1927;17(7):848.
15. Cuvier G. [Pathology of the german generals at the battle of the marne]. Presse Med. 1964;72:2119-20.
16. Boyd J. Tetanus in two world wars. Proc R Soc Med. 1959;52(2):109-10.
17. Wever P.C., van Bergen L. Prevention of tetanus during the First World War. Med Humanit. 2012;38(2):78–82.
18. Colebrook L. Almroth Wright; pioneer in immunology. Br Med J. 1953;2(4837):635-40.
19. Allison V.D. Personal recollections of Sir Almroth Wright and Sir Alexander Fleming. Ulster Med J. 1974; 43(2):89–98.
20. IVY R.H. The influenza epidemic of 1918. Personal experience of a medical officer in World War I. Mil Med. 1960; 125:620-2.
21. Robinson K.R. The role of nursing in the influenza epidemic of 1918–1919. Nurs Forum. 1990; 25(2):19–26.
22. Aminov R.I. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol. 2010; 1:134.
23. Ioset J.R., Kaur H. Simple field assays to check quality of current artemisinin-based antimalarial combination formulations. PLoS One. 2009; 4(9):e7270.
24. Yoshida T., Nasu H., Yamashita M. Construction of the control system of target molecule expression in Escherichia coli: application to a validation platform for bactericidal and bacteriostatic profiles due to suppression of a target molecule. FEMS Microbiol Lett. 2012;331(2):113-9.
25. Vinson C.G. Possible chemical nature of tobacco mosaic virus. Science. 1934;79(2059):548-9.
26. Stanley W.M. The inactivation of crystalline tobacco-mosaic virus protein. Science. 1936;83(2165):626-7.
27. Hey S.P., Kesselheim A.S. Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations. Hastings Cent Rep. 2017;47(2):16–20.
28. Lobanovska M., Pilla G. Penicillin’s Discovery and Antibiotic Resistance: Lessons for the Future? Yale J Biol Med. 2017;90(1):135-45.
29. Luepke K.H., Suda K.J., Boucher H., Russo R.L., Bonney M.W., Hunt T.D., et al. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacotherapy. 2017;37(1):71–84.
30. Finland M., Weinstein L. Complications induced by antimicrobial agents. N Engl J Med. 1953;248(6):220-6.
31. Johnston A.W. Aplastic anaemia following treatment with chloramphenicol: transfusion of polycythaemic blood using sequestrene. Lancet. 1954;267(6833):319.
32. Dameshek W. Chloramphenicol-a new warning. JAMA. 1960;174:1853-4.
33. Fleischmann R.D., Adams M.D., White O., Clayton R.A., Kirkness E.F., Kerlavage A.R., et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995;269(5223):496–512.
34. Tse B.N., Adalja A.A., Houchens C., Larsen J., Inglesby T.V., Hatchett R. Challenges and Opportunities of Nontraditional Approaches to Treating Bacterial Infections. Clin Infect Dis. 2017;65(3):495–500.
35. Svennebring A.M., Wikberg J.E. Net present value approaches for drug discovery. Springerplus. 2013;2(1):140.
36. Stachelhaus T., Schneider A., Marahiel M.A. Rational design of peptide antibiotics by targeted replacement of bacterial and fungal domains. Science. 1995;269(5220):69–72.
37. Ma Q.Q., Lv Y.F., Gu Y., Dong N., Li DS, Shan A.S. Rational design of cationic antimicrobial peptides by the tandem of leucine-rich repeat. Amino Acids. 2013;44(4):1215-24.
38. Boucher H.W., Talbot G.H., Dunne M.W. Dalbavancin or oritavancin for skin infections. N Engl J Med. 2014;371(12):1161-2.
39. Bernareggi A., Danese A., Cavenaghi L. Pharmacokinetics of A40926 in rats after single intravenous and subcutaneous doses. Antimicrob Agents Chemother. 1988;32(2):246-9.
40. Marcone G.L., Beltrametti F., Binda E., Carrano L., Foulston L., Hesketh A., et al. Novel mechanism of glycopeptide resistance in the A40926 producer Nonomuraea sp. ATCC 39727. Antimicrob Agents Chemother. 2010;54(6):2465-72.
41. Steiert M., Schmitz F.J. Dalbavancin (Biosearch Italia/Versicor). Curr Opin Investig Drugs. 2002;3(2):229-33.
42. Bosso J.A. The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy. 2005;25(10 Pt 2):55S-62S.
43. Domagk G. Twenty-five years of sulfonamide therapy. Ann N Y Acad Sci. 1957;69(3):380-4.
44. A G N. The Elixir Sulfanilamide-Massengill. Can Med Assoc J. 1937;37(6):590.
45. Gay F.P., Clark A.R. On the mode of action of sulfanilamide in experimental streptococcus empyema. J Exp Med. 1937;66(5):535-48.
46. Geiger J.C. Concerning Elixir of Sulfanilamide. Cal West Med. 1937;47(5):353.
47. Locke A., Locke R.B., Bragdon R.J., Mellon R.R. Fitness, sulfanilamide and pneumococcus infection in the rabbit. Science. 1937;86(2227):228-9.
48. Finkelstein R., Birkeland J.M. The mode of action of sulfanilamide and prontosil. Science. 1938;87(2263):441-2.
49. Hanigan W.C. Neurological surgery during the Great War: the influence of Colonel Cushing. Neurosurgery. 1988;23(3):283-94.
50. Domagk G. Br Med J. 1964;1(5391):1189.
51. Raju T.N. The Nobel chronicles. 1939: Gerhard Domagk (1895–1964). Lancet. 1999;353(9153):681.
52. Boozer J.S. Children of Hippocrates: doctors in Nazi Germany. Ann Am Acad Pol Soc Sci. 1980(450):83–97.
53. Levine C. What’s in a name? The Eppinger Prize and Nazi experiments. Hastings Cent Rep. 1984;14(6):3–4.
54. Kevorkian J. A brief history of experimentation on condemned and executed humans. J Natl Med Assoc. 1985;77(3):215-26.
55. Shuster E. American Doctors at the Nuremberg Medical Trial. Am J Public Health. 2018;108(1):47–52.
56. Harkness J.M. Nuremberg and the issue of wartime experiments on US prisoners. The Green Committee. JAMA. 1996;276(20):1672-5.
57. Adashi E.Y., Walters L.B., Menikoff J.A. The Belmont Report at 40: Reckoning With Time. Am J Public Health. 2018; 108(10):1345-8.
58. Merz J.F. The Nuremberg Code and Informed Consent for Research. JAMA. 2018;319(1):85-6.
59. Vonderlehr R.A. Increasing Opportunities for the Clinician in Public Health Work. J Natl Med Assoc. 1940;32(3):93-6.
60. Vonderlehr R.A. Concerning the fight against syphilis. Cal West Med. 1937;46(3):202.
61. Curran W.J. The tuskegee syphilis study. N Engl J Med. 1973;289(14):730-1.
62. White R.M. Unraveling the Tuskegee Study of Untreated Syphilis. Arch Intern Med. 2000;160(5):585-98.
63. Hill W.R. Problems arising in the treatment of syphilis with penicillin. N Engl J Med. 1946;235(26):919-24.
64. Barker W.F. Syphilitic aortitis with obstruction of multiple aortic ostia. N Engl J Med. 1949;241(14):524-7.
65. Heyman A., McCain J.R. Syphilis in pregnancy; a clinical study of factors responsible for congenital syphilis. N Engl J Med. 1949;241(24):960-4.
66. Brandt A.M. Racism and research: the case of the Tuskegee Syphilis Study. Hastings Cent Rep. 1978;8(6):21-9.
67. Beecher H.K. Ethics and clinical research. N Engl J Med. 1966;274(24):1354-60.
68. Welch C.E., Henry K., Beecher M.D. N Engl J Med. 1976;295(13):730.
69. Rothman D.J. Ethics and human experimentation. Henry Beecher revisited. N Engl J Med. 1987;317(19):1195-9.
70. Jones D.S., Grady C., Lederer S.E. “Ethics and Clinical Research” – The 50th Anniversary of Beecher’s Bombshell. N Engl J Med. 2016;374(24):2393-8.
71. Laurent J. Milgram’s shocking experiments; a case in the social construction of ‘science’. Indian J Hist Sci. 1987;22(3):247-72.
72. Gibson S. Obedience without orders: Expanding social psychology’s conception of ‘obedience’. Br J Soc Psychol. 2018.
73. Benedetti F. Beecher as Clinical Investigator: Pain and the Placebo Effect. Perspect Biol Med. 2016;59(1):37–45.
74. Senate USC. (Reprint of) National Research Act. Conference Report. Drug Res Rep. 1974;17(28):51-536.
75. Finlay K.A., Fernandez C.V. Failure to report and provide commentary on research ethics board approval and informed consent in medical journals. J Med Ethics. 2008;34(10):761-4.
76. Levine R.J., Lasagna L. Demystifying central review boards: current options and future directions. IRB. 2000;22(6):1–9.
77. Edgar H., Rothman D.J. The institutional review board and beyond: future challenges to the ethics of human experimentation. Milbank Q. 1995;73(4):489–506.
78. Quinn K. After the revolution: DRGs at age 30. Ann Intern Med. 2014;160(6):426-9.
79. Blum M.D., Graham D.J., McCloskey C.A. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis. 1994;18(6):946-50.
80. Guillard T., Pons S., Roux D., Pier G.B., Skurnik D. Antibiotic resistance and virulence: Understanding the link and its consequences for prophylaxis and therapy. Bioessays. 2016;38(7):682-93.
81. Skurnik D., Roux D., Pons S., Guillard T., Lu X., Cywes-Bentley C., et al. Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2016;71(4):927-35.
82. Spellberg B., Bartlett J.G., Gilbert D.N. The future of antibiotics and resistance. N Engl J Med. 2013;368(4):299–302.
83. Jawetz E. Antimicrobial chemotherapy. Annu Rev Microbiol. 1956;10:85-114.
84. Corrigan-Curay J., McKee A.E., Stein P. Breakthrough-Therapy Designation – An FDA Perspective. N Engl J Med. 2018;378(15):1457-8.
85. Woloshin S., Schwartz L.M., White B., Moore T.J. The Fate of FDA Postapproval Studies. N Engl J Med. 2017;377(12):1114-7.
86. Gellad W.F., Kesselheim A.S. Accelerated Approval and Expensive Drugs – A Challenging Combination. N Engl J Med. 2017;376(21):2001-4.
87. Resnic F.S., Matheny M.E. Medical Devices in the Real World. N Engl J Med. 2018;378(7):595-7.
88. Hudson A., Lopez E., Almalki A.J., Roe A.L., Calderón A.I. A Review of the Toxicity of Compounds Found in Herbal Dietary Supplements. Planta Med. 2018;84(9-10):613-26.
89. Salinas E. Access to Essential Medicines in the United States. N Engl J Med. 2016;375(9):904.
90. Ivanovska V., Leufkens H.G., Rademaker C.M., Zisovska E., Pijnenburg M.W., van Dijk L., et al. Are age-appropriate antibiotic formulations missing from the WHO list of essential medicines for children? A comparison study. Arch Dis Child. 2017;102(4):352-6.
91. Puthumana J., Wallach J.D., Ross J.S. Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation. JAMA. 2018;320(3):301-3.
92. Valiquette L., Laupland K.B. Antimicrobial shortages: Another hurdle for clinicians. Can J Infect Dis Med Microbiol. 2015; 26(2):67-8.
93. McLaughlin M. M, Skoglund E., Pentoney Z., Scheetz M.H. Developing a Method for Reporting Patient Harm Due to Antimicrobial Shortages. Infect Dis Ther. 2014;3(2):349-55.
94. Gilbert D.N., Edwards J.E. Is there hope for the prevention of future antimicrobial shortages? Clin Infect Dis. 2002;35(2):215-6; author reply 6–7.
95. Kessel J., Dolff B., Wichelhaus T., Keiner N., Hogardt M., Reinheimer C., et al. [Piperacillin/Tazobactam Shortage: Central Restriction and Alternative Recommendations as Effective Antibiotic-Stewardship Intervention at a Maximal Care Hospital]. Dtsch Med Wochenschr. 2018;143(8):e59-e67.
96. Nurse-Findlay S., Taylor M.M., Savage M., Mello M.B., Saliyou S., Lavayen M., et al. Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews. PLoS Med. 2017;14(12):e1002473.
97. Watkins D.A., Johnson C.O., Colquhoun S.M., Karthikeyan G., Beaton A., Bukhman G., et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. N Engl J Med. 2017;377(8):713-22.
98. Mensah G.A., Roth G.A., Sampson U.K., Moran A.E., Feigin V.L., Forouzanfar M.H., et al. Mortality from cardiovascular diseases in sub-Saharan Africa, 1990–2013: a systematic analysis of data from the Global Burden of Disease Study 2013. Cardiovasc J Afr. 2015;26(2 Suppl 1):S6-10.
99. Boucher H.W., Ambrose P.G., Chambers H.F., Ebright R.H., Jezek A., Murray B.E., et al. White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs. J Infect Dis. 2017;216(2):228-36.
100. Bloom G., Merrett G.B., Wilkinson A., Lin V., Paulin S. Antimicrobial resistance and universal health coverage. BMJ Glob Health. 2017;2(4):e000518.
101. Lowy F.D. How Staphylococcus aureus adapts to its host. N Engl J Med. 2011;364(21):1987-90.
102. Lowy F.D. Mapping the distribution of invasive Staphylococcus aureus across Europe. PLoS Med. 2010;7(1):e1000205.
103. Dyer O. Allergan transfers Restasis patent to Mohawk tribe to deter challenges from generics. BMJ. 2017;358:j4280.
104. Gavril D., Woerther P.L., Ben Lakhdar A., Mahjoubi L., Routier E., Chachaty E., et al. Invasive cutaneous infection due to Scopulariopsis brevicaulis unsuccessfully treated with high-dose micafungin in a neutropenic patient. Infection. 2017;45(3):361-3.
105. Hazen E.L., Brown R. Nystatin. Ann N Y Acad Sci. 1960;89:258-66.
106. Brown R., Hazen E.L. Present knowledge of nystatin, an antifungal antibiotic. Trans N Y Acad Sci. 1957;19(5):447-56.
107. Brown R., Hazen E.L., Mason A. Effect of fungicidin (nystatin) in mice injected with lethal mixtures of aureomycin and Candida albicans. Science. 1953;117(3048):609-10.
108. Hazen E.L., Brown R., Mason A. Protective action of fungicidin (nystatin) in mice against virulence enhancing activity of oxytetracycline on Candida albicans. Antibiot Chemother (Northfield). 1953;3(11):1125-8.
109. Hazen E.L., Brown R. Fungicidin, an antibiotic produced by a soil actinomycete. Proc Soc Exp Biol Med. 1951;76(1):93-7.
110. Årdal C., Baraldi E., Theuretzbacher U., Outterson K., Plahte J., Ciabuschi F., et al. Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. J Pharm Policy Pract. 2018;11:8.
111. Baraldi E., Lindahl O., Savic M., Findlay D., Årdal C. Antibiotic Pipeline Coordinators. J Law Med Ethics. 2018;46(1_suppl):25–31.
112. Savic M, Årdal C.A. Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics. J Law Med Ethics. 2018;46(1_suppl):9-24.
113. Storehagen L., Aftab F., Årdal C., Savic M., Røttingen J.A. Should Antibiotics Be Controlled Medicines? Lessons from the Controlled Drug Regimen. J Law Med Ethics. 2018;46(1_suppl):81–94.
114. Årdal C., Røttingen J.A. Open source drug discovery in practice: a case study. PLoS Negl Trop Dis. 2012;6(9):e1827.
115. Blum R., Stanton G.H., Sagi S., Richter E.D. ‘Ethnic cleansing’ bleaches the atrocities of genocide. Eur J Public Health. 2008;18(2):204-9.
116. Kellermann N.P. Epigenetic transmission of Holocaust trauma: can nightmares be inherited? Isr J Psychiatry Relat Sci. 2013;50(1):33-9.
117. Yehuda R., Lehrner A., Bierer L.M. The public reception of putative epigenetic mechanisms in the transgenerational effects of trauma. Environ Epigenet. 2018;4(2):dvy018.
118. Yehuda R., Daskalakis N.P., Bierer L.M., Bader H.N., Klengel T., Holsboer F., et al. Holocaust Exposure Induced Intergenerational Effects on FKBP5 Methylation. Biol Psychiatry. 2016;80(5):372-80.
119. DiDiodato G., Fruchter L. Antibiotic exposure and risk of community-associated Clostridium difficile infection: A self-controlled case series analysis. Am J Infect Control. 2018.
120. Lowe C.F., Payne M., Puddicombe D., Mah A., Wong D., Kirkwood A., et al. Antimicrobial stewardship for hospitalized patients with viral respiratory tract infections. Am J Infect Control. 2017.
121. Griffith R.S. Introduction to vancomycin. Rev Infect Dis. 1981;3 suppl:S200-4.
122. Griffith R.S. Vancomycin use-an historical review. J Antimicrob Chemother. 1984;14 Suppl D:1–5.
123. Darko W., Medicis J.J., Smith A., Guharoy R., Lehmann D.E. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy. 2003;23(5):643-50.
124. Elting L.S., Rubenstein E.B., Kurtin D., Rolston K.V., Fangtang J., Martin C.G., et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer. 1998;83(12):2597-607.
125. London A.J. Social value, clinical equipoise, and research in a public health emergency. Bioethics. 2018.
126. Cunny K.A., Miller H.W. Participation in clinical drug studies: motivations and barriers. Clin Ther. 1994;16(2):273-82; discussion 1–2.
127. Chen S.C., Sinaii N., Bedarida G., Gregorio M.A., Emanuel E., Grady C. Phase 1 healthy volunteer willingness to participate and enrollment preferences. Clin Trials. 2017;14(5):537-46.
128. Grady C., Bedarida G., Sinaii N., Gregorio M.A., Emanuel E.J. Motivations, enrollment decisions, and socio-demographic characteristics of healthy volunteers in phase 1 research. Clin Trials. 2017;14(5):526-36.
129. Comerci G., Katzman J., Duhigg D. Controlling the Swing of the Opioid Pendulum. N Engl J Med. 2018;378(8):691-3.
130. Opiate deaths demand serious action. Nature. 2017; 551(7682):541-2.
131. Salamone F.R. Clinical pharmacology of antibiotics. Sulbactam/ampicillin. Infect Control Hosp Epidemiol. 1988;9(7):323-7.
132. Centers for Disease Control and Prevention HHS. World Trade Center Health Program; addition of certain types of cancer to the list of WTC-related health conditions. Final rule. Fed Regist. 2012;77(177):56138-68.
133. Durán Graeff L., Seidel D., Vehreschild M.J., Hamprecht A., Kindo A., Racil Z., et al. Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry. Mycoses. 2017;60(4):273-9.
134. Vaux S., Criscuolo A., Desnos-Ollivier M., Diancourt L., Tarnaud C., Vandenbogaert M., et al. Multicenter outbreak of infections by Saprochaete clavata, an unrecognized opportunistic fungal pathogen. MBio. 2014;5(6).
135. Kontoyiannis D.P., Perlin D.S., Roilides E., Walsh T.J. What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis? Clin Infect Dis. 2013;57(6):853-9.
136. McCarthy M., Rosengart A., Schuetz A.N., Kontoyiannis D.P., Walsh T.J. Mold infections of the central nervous system. N Engl J Med. 2014;371(2):150-60.
137. Montgomery M.P., Robertson S., Koski L., Salehi E., Stevenson L.M., Silver R., et al. Multidrug-Resistant Campylobacter jejuni Outbreak Linked to Puppy Exposure – United States, 2016–2018. MMWR Morb Mortal Wkly Rep. 2018;67(37):1032-5.
138. Ström G., Boqvist S., Albihn A., Fernström L.L., Andersson Djurfeldt A., Sokerya S., et al. Antimicrobials in small-scale urban pig farming in a lower middle-income country – arbitrary use and high resistance levels. Antimicrob Resist Infect Control. 2018;7:35.
139. Abdel-Wahab N., Shah M., Suarez-Almazor M.E. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One. 2016;11(7):e0160221.
140. Gajewski T.F. Fast Forward – Neoadjuvant Cancer Immunotherapy. N Engl J Med. 2018;378(21):2034-5.
141. Garon E.B. Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients. N Engl J Med. 2017; 376(25):2483-5.
142. Caliendo A.M., Hodinka R.L. A CRISPR Way to Diagnose Infectious Diseases. N Engl J Med. 2017;377(17):1685-7.
143. Graham D.B., Root D.E. Resources for the design of CRISPR gene editing experiments. Genome Biol. 2015;16:260.
144. Reardon S. Modified viruses deliver death to antibiotic-resistant bacteria. Nature. 2017;546(7660):586-7.
145. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597–602.
146. Marra A. NDM-1: a local clone emerges with worldwide aspirations. Future Microbiol. 2011;6(2):137-41.
147. Sepkowitz K.A. Finland, Weinstein, and the birth of antibiotic regret. N Engl J Med. 2012;367(2):102-3.
148. Wring S.A., Randolph R., Park S, Abruzzo G., Chen Q., Flattery A., et al. SCY-078 A First in Class Orally Active Antifungal Glucan Synthesis Inhibitor: Pre-Clinical Pharmacokinetics and Pharmacodynamic Target in Murine Models of Disseminated Candidiasis. Antimicrob Agents Chemother. 2017.
149. Satoh K., Makimura K., Hasumi Y., Nishiyama Y., Uchida K., Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41-4.
150. Veve M.P., Wagner J.L. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. Pharmacotherapy. 2018; 38(9):935-46.
151. Lomovskaya O., Sun D., Rubio-Aparicio D., Nelson K., Tsivkovski R., Griffith D.C., et al. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017.
152. Ito A., Nishikawa T., Matsumoto S., Yoshizawa H., Sato T., Nakamura R., et al. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(12):7396-401.
153. Flexner S., Jobling J.W. An analysis of four hundred cases of epidemic meningitis treated with the anti-meningitis serum. J Exp Med. 1908;10(5):690–733.
154. Schuch R., Nelson D., Fischetti V.A. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature. 2002;418(6900):884-9.
155. Fischetti V.A., Gotschlich E.C., Bernheimer A.W. Purification and physical properties of group C streptococcal phage-associated lysin. J Exp Med. 1971;133(5):1105-17.
156. Bush L.M., Abrams B.H., Beall A., Johnson C.C. Index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med. 2001;345(22):1607-10.
157. Revich B., Tokarevich N., Parkinson A.J. Climate change and zoonotic infections in the Russian Arctic. Int J Circumpolar Health. 2012;71:18792.
158. Slocum AMY. A surgeon’s nightmare: pyoderma gangrenosum with pathergy effect mimicking necrotising fasciitis. BMJ Case Rep. 2017;2017.
159. Cameron D.J. An appraisal of “chronic Lyme disease”. N Engl J Med. 2008;358(4):429-30; author reply 30-1.
160. Drapkin M.S. An appraisal of “chronic Lyme disease”. N Engl J Med. 2008;358(4):430; author reply -1.
161. Feder H.M., Johnson B.J., O’Connell S., Shapiro E.D., Steere A.C., Wormser G.P., et al. A critical appraisal of “chronic Lyme disease”. N Engl J Med. 2007;357(14):1422-30.
162. Donta S.T. Treatment of patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345(19):1424; author reply 5.
163. Simon M.A., Haring R., Rodriguez E.M., González E., Kaur J.S., Kirschner M., et al. Improving Research Literacy in Diverse Minority Populations with a Novel Communication Tool. J Cancer Educ. 2018.
164. Tahhan A.S., Vaduganathan M., Greene S.J., Fonarow G.C., Fiuzat M., Jessup M., et al. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. JAMA Cardiol. 2018.
165. Virgili A., Zampino M.R., Mantovani L. Fungal skin infections in organ transplant recipients. Am J Clin Dermatol. 2002;3(1):19–35.
166. Hammarlöf D.L., Kröger C., Owen S.V., Canals R., Lacharme-Lora L., Wenner N., et al. Role of a single noncoding nucleotide in the evolution of an epidemic African clade of. Proc Natl Acad Sci U S A. 2018;115(11):E2614-E23.
167. Small K.W., Chan C.K., Silva-Garcia R., Walsh T.J. Onset of an outbreak of Bipolaris hawaiiensis fungal endophthalmitis after intravitreal injections of triamcinolone. Ophthalmology. 2014;121(4):952-8.
168. Foolad F., Taylor B.D., Shelburne S.A., Arias C.A., Aitken S.L. Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review. J Antimicrob Chemother. 2018;73(9):2277-83.
169. Mylonakis E., Clancy C.J., Ostrosky-Zeichner L., Garey K.W., Alangaden G.J., Vazquez J.A., et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60(6):892-9.
170. Hover B.M., Kim S.H., Katz M., Charlop-Powers Z., Owen J.G., Ternei M.A., et al. Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. Nat Microbiol. 2018;3(4):415-22.
171. Relman A.S. What you always wanted to know about the Howard Hughes Medical Institute but were afraid to ask. N Engl J Med. 1978;299(23):1303-5.
172. Nichols D., Cahoon N., Trakhtenberg E.M., Pham L., Mehta A., Belanger A., et al. Use of ichip for high-throughput in situ cultivation of “uncultivable” microbial species. Appl Environ Microbiol. 2010;76(8):2445-50.
173. Piddock L.J. Teixobactin, the first of a new class of antibiotics discovered by iChip technology? J Antimicrob Chemother. 2015;70(10):2679-80.
174. Sherpa R.T., Reese C.J., Montazeri Aliabadi H. Application of iChip to Grow “Uncultivable” Microorganisms and its Impact on Antibiotic Discovery. J Pharm Pharm Sci. 2015;18(3):303-15.
175. Ling L.L., Schneider T., Peoples A.J., Spoering A.L., Engels I., Conlon B.P., et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015; 517(7535):455-9.
176. Kaeberlein T., Lewis K., Epstein S.S. Isolating “uncultivable” microorganisms in pure culture in a simulated natural environment. Science. 2002;296(5570):1127-9.
Macfarlane, Gwyn. Alexander Fleming. London: Hogarth Press (Chatto & Windus); 1984.
Lax, Eric. The Mold In Dr. Florey’s Coat. New York: H. Holt; 2004.
Rosen, William. Miracle Cure. New York: Viking; 2017.
Brown, Kevin. Penicillin Man. Sutton Publishing Limited; 2004.
Hager, Thomas. The Demon Under the Microscope. Harmony; 2006.
Martin, Barbara. Elixir. Barkberry Press; 2014.
Spitz, Vivien. Doctors From Hell. Sentient; 2005.
Jones, James. Bad Blood. Free Press; 1993.
Stark, Laura. Behind Closed Doors. University of Chicago; 2012.
Hilts, Phillip. Protecting America’s Health. Knopf; 2003.
Sinclair, Upton. The Jungle. New York: New American Library; 1906.
На русском: Джунгли: роман / Э. Синклер; пер. с англ. Д.М. Горфинкель и Э.Л. Линецкой; ил. А. Васина. – Москва: Гослитиздат, 1956.
Drea, Edward. War At The End Of The World. CreateSpace; 2015.
Chernow, Ron. Titan. Vintage; 2004.
На русском:
Чернов Рональд, Титан. Жизнь сэра Джона Д. Рокфеллера. – Москва: Крон-Пресс, 1999.
Blum, Deborah. The Poison Squad. Penguin Press; 2018.
Войти с помощью соц. сетей: